Calcipotriol enhances efficacy of imatinib and nilotinib on cells derived from plexiform neurofibroma

Y Zhao, M Yan, V Mautner, R Smeets… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Plexiform neurofibromas (PNFs) are benign tumors composed mainly of
tumorous Schwann cells and non-tumorous fibroblasts. This study examined the possible …

Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model

M Demestre, J Herzberg, N Holtkamp, C Hagel… - Journal of neuro …, 2010 - Springer
Plexiform neurofibromas (PNF), one of the major features of neurofibromatosis type 1 (NF1),
are characterized by complex cellular composition and mostly slow but variable growth …

[HTML][HTML] Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo

J Wei, M Freytag, Y Schober, WA Nockher… - PLoS …, 2014 - journals.plos.org
Plexiform neurofibromas (PNFs) are benign nerve sheath tumors mostly associated with
neurofibromatosis type 1. They often extend through multiple layers of tissue and therefore …

Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas.

KA Robertson, DC Bowers, F Yang, T Vik… - Journal of Clinical …, 2011 - ascopubs.org
10030 Background: NF1 is a common inherited disorder resulting from mutations in the
neurofibromin gene resulting in a variety of tumors. PN occur in 20-40% of NF1 patients and …

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial

KA Robertson, G Nalepa, FC Yang, DC Bowers… - The lancet …, 2012 - thelancet.com
Background Plexiform neurofibromas are slow-growing chemoradiotherapy-resistant
tumours arising in patients with neurofibromatosis type 1 (NF1). Currently, there are no …

[HTML][HTML] Pilot phase II trial of imatinib mesylate in neurofibromatosis type 1 patients with plexiform neurofibromas

KA Robertson, G Nalepa, FC Yang… - The Lancet …, 2012 - ncbi.nlm.nih.gov
BACKGROUND Plexiform neurofibromas (PN) are slow growing chemoradiotherapy
resistant tumours arising in patients with neurofibromatosis type I (NF1). Currently there are …

[HTML][HTML] Plexiform neurofibroma treated with pharmacopuncture

C Lim, K Kwon, K Lee - journal of pharmacopuncture, 2014 - ncbi.nlm.nih.gov
Objectives: The purpose of this study is to report a case of a plexiform neurofibroma (PNF) in
the pelvic region treated with sweet bee venom (SBV) and mountain ginseng …

[HTML][HTML] Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures

W Jiang, VF Mautner, RE Friedrich… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Background and Purpose Individualized drug testing for tumors using a strategy analogous
to antibiotic tests for infectious diseases would be highly desirable for personalized and …

Sirolimus for progressive neurofibromatosis type 1–associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study

B Weiss, BC Widemann, P Wolters, E Dombi… - Neuro …, 2015 - academic.oup.com
Abstract Background Plexiform neurofibromas (PNs) are benign peripheral nerve sheath
tumors that arise in one-third of individuals with neurofibromatosis type 1 (NF1). They may …

Propranolol Specifically suppresses the viability of tumorous schwann cells derived from plexiform neurofibromas in vitro

Z Zou, L Guo, V Mautner, R Smeets, L Kiuwe… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Plexiform neurofibromas (PNFs) are benign tumors of the periph eral
nerves sheath, which can damage neighboring organs, impair functions, cause pain and …